Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02RNR
|
|||
Former ID |
DIB011041
|
|||
Drug Name |
LB-100
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Astrocytoma [ICD-11: 2A00.0Y] | Phase 2 | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
Structure |
Download2D MOL |
|||
Formula |
C13H20N2O4
|
|||
Canonical SMILES |
CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3
|
|||
InChI |
1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)
|
|||
InChIKey |
JUQMLSGOTNKJKI-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03027388) Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. U.S. National Institutes of Health. | |||
REF 2 | Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72. | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.